Genomic medicine: Exploring the basis of a new approach to endocrine hypertension

Annals of the New York Academy of Sciences

Volumn 970, Issue , 2002, Pages 177-192

  Alesci, Salvatore ^a,b   Chrousos, George P ^a   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Adrenal cancer; Adrenal gland; Adrenocortical carcinoma; Congenital adrenal hyperplasia; Cushing's syndrome; Endocrine hypertension; Gene therapy; Hyperaldosteronism; Pheochromocytoma

Indexed keywords

DNA; VIRUS VECTOR;

ADRENAL CANCER; ADRENAL GLAND; ADRENAL TUMOR; CLINICAL FEATURE; CONFERENCE PAPER; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENOMICS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOPHYSIS TUMOR;

EID: 0037024523     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04424.x     Document Type: Conference Paper

References (84)

1. Blaese, R.M. et al. 1995. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270: 475-480.
2. Anonymous. 1999. Gene transfer and therapy clinical trials - Update. Part I: Countries, diseases, clinical trial phases, routes of administration. J. Gene Med. 1: 71-73.
3. Cavazzana-Calvo, M. et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
4. Kay, M.A. et al. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24: 257-261.
5. Verma, I.M. & N. Somia. 1997. Gene therapy - Promises, problems and prospects. Nature 389: 239-242.
6. Amado, R.G. & I.S. Chen. 1999. Lentiviral vectors - The promise of gene therapy within reach? Science 285: 674-676.
7. Monahan, P.E. & R.J. Samulski. 2000. AAV vectors: is clinical success on the horizon? Gene Ther. 7: 24-30.
8. Shenk, T. 1996. Adenoviridae: The viruses and their replication. In Fundamental Virology. B.N. Fields, Ed.: 979-1016. Lippincot-Raven. Philadelphia, PA.
9. Graham, F. & L. Prevec. 1991. Manipulation of adenovirus vectors. In Methods in Molecular Biology. Gene Transfer and Expression Techniques, Vol. 7. E.M.J. Walker, Ed.: 109-128. Humana Press. Clifton, NJ.
10. Harui, A. et al. 1999. Frequency and stability of chromosomal integration of adenovirus vectors. J. Virol. 73: 6141-6146.
11. Newman, K.D. et al. 1995. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J. Clin. Invest. 96: 2955-2965.
12. Wilson, J.M. 1996. Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 334: 1185-1187.
13. Hermiston, T. 2000. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J. Clin. Invest. 105: 1169-1172.
14. Alemany, R., C. Balague & D.T. Curiel. 2000. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18: 723-727.
15. Coffin, J. 1996. Retroviridae: The viruses and their classification. In Filelds Virology. B.N. Fields, Ed.: 1767-1848. Lippincot-Raven. Philadelphia, PA.
16. Miller, A. 1997. Development and application of retroviral vectors. In Retroviruses. J.M Coffin and H.E. Varmus, Eds.: 437-473. Cold Spring Harbor Laboratory Press. Plainview, NY.
17. Nabel, E.G. & G.J. Nabel. 1994. Complex models for the study of gene function in cardiovascular biology. Annu. Rev. Physiol. 56: 741-761.
18. Lewis, P., M. Hensel & M. Emerman. 1992. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 11: 3053-3058.
19. Naldini, L. et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
20. Poeschla, E., P. Corbeau & F. Wong-Staal. 1996. Development of HIV vectors for anti-HIV gene therapy. Proc. Natl. Acad Sci USA 93: 11395-11399.
21. Zufferey, R. et al. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15: 871-875.
22. Miyoshi, H. et al. 1998. Development of a self-inactivating lentivirus vector. J. Virol. 72: 8150-8157.
23. Berns, K. 1996. Parvoviridae: The viruses and their replication. In Fields Virology. B.N. Fields, Ed.: 2173-2197. Lippincot-Raven. Philadelphia, PA.
24. Carter, B.J. 1992. Adeno-associated virus vectors. Curr. Opin. Biotechnol. 3: 533-539.
25. Kotin, R.M., R.M. Linden & K.I. Berns. 1992. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 11: 5071-5078.
26. Donahue, B.A. et al. 1999. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J. Gene Med. 1: 31-42.
27. Conrad, C.K. et al. 1996. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. 3: 658-668.
28. Wagner, J.A. et al. 1998. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351: 1702-1703.
29. Malik, P. et al. 1997. Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. J. Virol. 71: 1776-1783.
30. Chirmule, N. et al. 1999. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6: 1574-1583.
31. Ferrari, F.K. et al. 1997. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat. Med. 3: 1295-1297.
32. Krisky, D.M. et al. 1998. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5: 1593-1603.
33. Sanda, M.G. et al. 1999. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53: 260-266.
34. Polo, J.M. et al. 1999. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc. Natl. Acad. Sci. USA 96: 4598-4603.
35. Nakanishi, M. et al. 1999. Gene delivery systems using the Sendal virus. Mol. Membr. Biol. 16: 123-127.
36. Robertson, E.S., T. Ooka & E.D. Kieff. 1996. Epstein-Barr virus vectors for gene delivery to B lymphocytes. Proc. Natl. Acad. Sci. USA 93: 11334-11340.
37. Duisit, G. et al. 1999. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum. Gene Ther. 10: 189-200.
38. Fisher, K.J. et al. 1996. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum. Gene Ther. 7: 2079-2087.
39. Hengge, U.R. et al. 1995. Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nat. Genet. 10: 161-166.
40. Wolff, J.A. et al. 1990. Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
41. Sikes, M.L. et al. 1994. In vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. Hum. Gene Ther. 5: 837-844.
42. Malone, R.W. et al. 1994. Dexamethasone enhancement of gene expression after direct hepatic DNA injection. J. Biol. Chem. 269: 29903-29907.
43. Riessen, R. et al. 1993. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum. Gene Ther. 4: 749-758.
44. Wolff, J.A. et al. 1992. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1: 363-369.
45. Wang, R. et al. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282: 476-480.
46. Heath, T.D., N.G. Lopez & D. Papahadjopoulos. 1985. The effects of liposome size and surface charge on liposome-mediated delivery of methotrexate-gamma-aspartate to cells in vitro. Biochim. Biophys. Acta 820: 74-84.
47. Felgner, J.H. et al. 1994. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269: 2550-2561.
48. Felgner, P.L. et al. 1987. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84: 7413-7417.
49. Li, S. & L. Huang. 2000. Nonviral gene therapy: Promises and challenges. Gene Ther. 7: 31-34.
50. Boussif, O., M.A. Zanta & J.P. Behr. 1996. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther. 3: 1074-1080.
51. Kaneda, Y. 1999. Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. Mol. Membr. Biol. 16: 119-122.
52. Condon, C. et al. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2: 1122-1128.
53. Mathei, C., P. Van Damme & A. Meheus. 1997. Hepatitis B vaccine administration: Comparison between jet-gun and syringe and needle. Vaccine 15: 402-404.
54. Tacket, C.O. et al. 1999. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17: 2826-2829.
55. Nishi, T. et al. 1997. Treatment of cancer using pulsed electric field in combination with chemotherapeutic agents or genes. Hum. Cell 10: 81-86.
56. Boekstegers, P. et al. 2000. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther. 7: 232-240.
57. Banai, S. et al. 1994. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89: 2183-2189.
58. Asahara, T., C. Kalka & J.M. Isner. 2000. Stem cell therapy and gene transfer for regeneration. Gene Ther. 7: 451-457.
59. Gage, F.H. 1998. Cell therapy. Nature 392: 18-24.
60. Kasperlik-Zaluska, A.A. et al. 1995. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 75: 2587-2591.
61. Demeure, M.J. & L.B. Somberg. 1998. Functioning and nonfunctioning adrenocortical carcinoma: Clinical presentation and therapeutic strategies. Surg. Oncol. Clin. N. Am. 7: 791-805.
62. Lo, C.Y. et al. 1996. Primary aldosteronism. Results of surgical treatment. Ann. Surg. 224: 125-130.
63. Melby, J.C. 1989. Clinical review 1: Endocrine hypertension. J. Clin. Endocrinol. Metab. 69: 697-703.
64. Ulick, S. & M.D. Chu. 1982. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clin. Exp. Hypertens. A 4: 1771-1777.
65. Koch, C.A. et al. 2001. Genetic aspects of pheochromocytoma. Endocr. Regul. 35: 43-52.
66. Pacak, K. et al. 2001. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann. Intern. Med. 134: 315-329.
67. Schachtner, S. et al. 1999. Temporally regulated expression patterns following in utero adenovirus-mediated gene transfer. Gene Ther. 6: 1249-1257.
68. Senoo, M. et al. 2000. Adenovirus-mediated in utero gene transfer in mice and guinea pigs: Tissue distribution of recombinant adenovirus determined by quantitative TaqMan-polymerase chain reaction assay. Mol. Genet. Metab. 69: 269-276.
69. Yang, E.Y. et al. 1999. BAPS Prize - 1997. Fetal gene therapy: Efficacy, toxicity, and immunologic effects of early gestation recombinant adenovirus. British Association of Paediatric Surgeons. J. Pediatr. Surg. 34: 235-241.
70. Tajima, T. et al. 1999. Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochromeP450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice. Gene Ther. 6: 1898-1903.
71. Hanke, C.J. et al. 2000. Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension 35: 324-328.
72. Chuman, Y., Z. Zhan & T. Fojo. 2000. Construction of gene therapy vectors targeting adrenocortical cells: Enhancement of activity and specificity with agents modulating the cyclic adenosine 3′,5′-monophosphate pathway. J. Clin. Endocrinol. Metab. 85: 253-262.
73. Alesci, S. et al. 2002. Adenoviral vectors can impair adrenocortical steroidogenesis: Clinical implications for natural infections and gene therapy. Proc. Natl. Acad. Sci. USA 99: 7484-7489.
74. Hornsby, P.J. 2001. Transplantation of adrenocortical cells. Rev. Endocr. Metab. Disord. 2: 313-321.
75. Littley, M.D. et al. 1991. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Q. J. Med. 78: 265-274.
76. Davis, J.R. et al. 1999. Gene therapy for pituitary tumours. Endocr. Relat. Cancer 6: 475-481.
77. Castro, M.G. et al. 1999. Cell-type specific expression in the pituitary: Physiology and gene therapy. Biochem. Soc. Trans. 27: 858-863.
78. Lee, E.J. et al. 1999. Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J. Clin. Endocrinol. Metab. 84: 786-794.
79. Neill, J.D. et al. 1999. High efficiency method for gene transfer in normal pituitary gonadotropes: Adenoviral-mediated expression of G protein-coupled receptor kinase 2 suppresses luteinizing hormone secretion. Endocrinology 140: 2562-2569.
80. Castro, M.G. et al. 1997. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: Long term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology 138: 2184-2194.
81. Windeatt, S. et al. 2000. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas. J. Clin. Endocrinol. Metab. 85: 1296-1305.
82. Wolf, D. et al. 1988. Retrovirus-mediated gene transfer of beta-nerve growth factor into mouse pituitary line AtT-20. Mol. Biol. Med. 5: 43-59.
83. Horellou, P. et al. 1989. Retroviral transfer of a human tyrosine hydroxylase cDNA in various cell lines: Regulated release of dopamine in mouse anterior pituitary AtT-20 cells. Proc. Natl. Acad. Sci. USA 86: 7233-7237.
84. Goya, R.G. et al. 1998. Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells. Mol. Cell. Endocrinol. 139: 199-207.